Attached files

file filename
EX-99.1 - EXHIBIT 99.1 - ACURA PHARMACEUTICALS, INCv300140_ex99-1.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D. C. 20549

 

 

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act Of 1934

 

January 23, 2012

Date of Report (Date of earliest event reported)

 

 

 

 

ACURA PHARMACEUTICALS, INC.

(Exact Name of Registrant as Specified in Charter)

 

 

 

State of New York 1-10113 11-0853640
(State of Other Jurisdiction (Commission File Number)  (I.R.S. Employer
of Incorporation)  Identification Number)

 

616 N. North Court, Suite 120

Palatine, Illinois 60067

(Address of principal executive offices) (Zip Code)

 

(847) 705-7709

(Registrant’s telephone number, including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17CFR 240.14a-12)
   
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17CFR240.14d-2(b))
   
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17CFR 240.13e-4(c))
   
 
 

 

Item 8.01      Other Events

 

On January 23, 2012 we issued a press release providing an update on the commercialization by Pfizer, Inc. of OXECTA™ (oxycodone HCl, USP) Tablets, which we licensed to it. A copy of our press release is being filed as Exhibit 99.1 hereto and is incorporated herein by reference.

 

Item 9.01      Financial Statements and Exhibits

 

Exhibit Number   Description
     
99.1   Press Release dated January 23, 2012
     

 

 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

  ACURA PHARMACEUTICALS, INC.
     
  By: /s/ Peter A. Clemens
    Peter A. Clemens
    Senior Vice President & Chief Financial Officer

 

Date:  January 23, 2012

 

 
 

Exhibit Index 

Exhibit Number   Description
     
99.1   Press Release dated January 23, 2012